Search research articles
Contact Us
Filters
Showing results (141-150 of 154) with videos related to
Page
of 16
Sort By:
Cancer
|
April 22, 2022
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
Ajay Sheshadri, Alberto A Goizueta, Vickie R Shannon, et al.
JCO Precision Oncology
|
April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity
Mitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Cancers
|
December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer
Hui Li, Lingzhi Hong, Pedro Rocha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
Roshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications
|
July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications
|
April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights
Sheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.
Nature Communications
|
July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC
Maliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 154) with videos related to
Sort By:
Page
of 16
Cancer
|
April 22, 2022
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study
Ajay Sheshadri, Alberto A Goizueta, Vickie R Shannon, et al.
JCO Precision Oncology
|
April 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity
Mitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, et al.
Cancers
|
December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer
Hui Li, Lingzhi Hong, Pedro Rocha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
Roshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications
|
July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications
|
April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights
Sheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.
Nature Communications
|
July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC
Maliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Page
of 16